ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

Similar documents
Immunotherapy in Oncology

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA

Sound Off DR. GOOGLE S ROLE IN PRE-DIAGNOSIS THROUGH TREATMENT. Ipsos SMX. June 2014

CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES QUALITATIVE RESEARCH THROUGH A BEHAVIORAL ECONOMIC LENS

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020

Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer,

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

Novartis: tackling adherence. ESPACOMP, September, 2010

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco

Radiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013

NAVIFY Tumor Board NAVIFY

Cyclokat (Dry Eye Syndrome)

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

Asia-Pacific Electrophysiology Market Outlook to 2020

Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

NCCN TRENDS DEMOGRAPHICS. Results: January 2013 NON-SMALL CELL LUNG CANCER. Distribution of Respondent Types (n = 1,055) Page 1

OAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING. September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV. For the Life Sciences Industry

Imaging Systems. Gene Saragnese EVP and GM Imaging Systems

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

Value growth in Human Nutrition & Health

Chronic Myeloid Leukemia (CML)

Integrating Project Management Standards within Business Technology Management (BTM)

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

Boehringer Ingelheim Pharmaceuticals, Inc. & Univision. Making Diabetic Hispanics Healthier

2018 Global Value-based Digital Dental Competitive Strategy Innovation and Leadership Award

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013

eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

Russia Cardiac Assist Devices Market Outlook to 2021

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

Mexico Ostomy Drainage Bags Market Outlook to 2020

Bariatric Surgery Devices - North America Analysis and Market Forecasts

2015 Investor Conference

Genomic Health. Kim Popovits, Chairman, CEO and President

Opportunities and Challenges in the Development of Companion Diagnostics

Transforming health through IT

The Cigarette Market in Greece

Partnering for Growth

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013

Global In-Vitro-Fertilization Market: Trends and Opportunities ( )

Member-centered cancer care In Georgia

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Watson Summit Prague 2017

GLOBAL NEUROSTIMULATION MARKET

MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

DIGITAL DIABETES CARE MARKET READY TO TAKE OFF

Corporate Presentation Fourth Quarter 2017

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

October 4 6, 2017 The W Hotel, Chicago, IL

View Report Details. Global Coronary Stent Market

Jefferies 2014 Global Healthcare Conference November Because people depend on us

Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics

Walgreens. Specialty Pharmacy Marketing Video

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan

ph Meters Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

Purolite Life Sciences Brand Positioning Catalyst

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

Introducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Myriad Genetics Corporate Presentation 06/13/2018

Transcription:

CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

AT KANTAR HEALTH, ONCOLOGY IS WHAT WE DO! WE ARE GLOBAL EXPERTS IN BRINGING TOGETHER SCIENTIFIC AND COMMERCIAL RESEARCH TO DELIVER THE UNIQUE ONCOLOGY INSIGHTS AND COMMERCIAL STRATEGIES YOU NEED TO ACHIEVE BRAND SUCCESS. Kantar Health oncology solutions offers: + + 25+ years of deep oncology expertise and thought leadership. + + More than 100 dedicated oncology experts. + + 65+ PhDs, Pharm D, and MDs. + + 30 ex-pharma market access and commercial brand experts. + + 400+ market researchers, consultants, data scientists and creatives. + + Offices across the globe, on 5 continents and in 40 countries. + + 500+ custom oncology engagements in the last year alone covering more than 50 solid tumors and hematologic malignancies. + + A wide breadth of work with more than 150 oncology clients, including Big Pharma, BioTech, research and non-profit companies. + + An extensive published research record, with more than 120 oncologyrelated publications in conferences and medical journals. + + Impactful global qualitative and quantitative research, with experts who have native language skills. WORLD CLASS EXPERTISE, EXPERIENCE AND DATA ASSETS Kantar Health oncology solutions is the one place where Expertise, Experience and proprietary data resources intersect to deliver valuable insights to help you navigate the complex and everevolving oncology landscape. Simply, our experts convert complex nuances within the oncology landscape into simple, actionable business solutions. We re recognized globally as leaders in oncology consulting and market research by the world s most trusted oncology companies. We ll provide you with the insights, resources, and data needed to determine commercial potential and optimal market strategy, ultimately increasing the probability of commercial success. Kantar Health has the unique ability to collect, analyze, and interpret customized datasets, including linked data sources, enabling us to make strategic recommendations for winning commercial decisions. + + Proprietary data resources not found anywhere else in the industry. Our engagements span the product lifecycle from early-stage/discovery to post-marketing/surveillance. Only Kantar Health oncology solutions combines experts, data and insights with the analytics and tools necessary for product growth. 2 3

FOCUSED: THREE AREAS OF DISCIPLINE Our oncology experts focus on three areas that address key elements across the product lifecycle: Portfolio Planning, Clinical Development Strategy and Commercial Planning and Insights are the disciplines that form the structural foundation of Kantar Health Oncology. PORTFOLIO PLANNING CLINICAL DEVELOPMENT STRATEGY COMMERCIAL PLANNING & INSIGHTS Portfolio Prioritization Clinical Trial Optimization Market Landscape Assessment Competitive Intelligence Market Sizing & Epidemiology Patient Journey/Buying Process Clinical Evaluations Tumor Landscape Assessments Segmentation Competitive Event Assessment Competitive Positioning Analysis Brand Positioning Epidemiology/Patient Targeting Target Product Profile Assessment Key Influencer/Stakeholder Mapping Market Access & Pricing KOL Assessment Brand Equity Evaluation: PINNAKLE Brand & Franchise Commercial Strategy Qualitative & Quantitative Market Research Pre-clinical 4 Pre-launch Launch Post Launch Brand Optimization 5

DEDICATED: SIX EXPERT ONCOLOGY TEAMS Oncology is what we do, and Kantar Health s oncology solutions are supported by six expert oncology teams that provide specialized knowledge and proficiency related to specific areas of the oncology market. Our clients receive exclusive access to oncology stakeholders through Kantar s Lightspeed panel of payors and providers CLINICAL AND SCIENTIFIC CONSULTING FORECASTING AND ANALYTICS EPIDEMIOLOGY QUALITATIVE AND QUANTITATIVE RESEARCH & INSIGHTS ANALYTICS MARKET ACCESS & COMMERCIAL STRATEGY REAL WORLD EVIDENCE While each team has their own expertise, Kantar Health brings together multiple teams to provide creative, innovative solutions to your specific business needs no request is too big or small. We work with a blended team of epidemiology, oncology consulting, and forecasting experts to determine how new data and current agents will shape your agent s entry into the market. We leverage the knowledge of oncology consulting, health outcomes, market access, and marketing insights to build patient, physician, payer, and / or caregiver preference studies to better understand the picture of what patients and providers hope to achieve with new drug regimens. 6 7

HERITAGE: PROPRIETARY ONCOLOGY RESOURCES Kantar Health oncology solutions provides clients with a heritage of proprietary data resources not found anywhere else in the industry! For more than 20 years we have supplied the industry with a wide variety of oncology resources that the world s top oncology companies depend on. 8 9

CANCERMPACT CANCERLANDSCAPE TM ONCOLOGY FORECAST ARCHITECT ONCOLOGY MARKET ACCESS Getting from A to Z begins with CancerMPact the premier global oncology intelligence resource. CancerMPact features four integrated modules designed to provide clients with comprehensive business insights for the dynamic oncology landscape. CancerMPact covers more than 37 different tumor types across the US, EU-5, Japan, China and 9 additional countries. 4 MODULES Patient Metrics this cancer epidemiology module leverages data from cancer registries and combine it with expert analysis to act as the starting point for understanding your target population together with detailed treatment data to size any given tumor type. The CancerLandscape platform is an innovative, dynamic, webbased solution with an easy to navigate, visually impactful and highly interactive dashboard that makes data easy to interpret. Offering fast navigation of large datasets to better understand oncology medicine opportunities and the competitive landscape, CancerLandscape assists users in evaluating business development and licensing opportunities, identifying novel targets for drug development, comparing company pipelines, and understanding the competitive landscapes in multiple tumor types. Oncology Forecast Architect offers the flexibility to meet the unique requirements of oncology product forecasting and the functionality to simplify the modeling process so that users may focus on assumptions. Our cancer patient flow forecast approach takes into account: the partitioning of patients into commercially relevant segments, including lines of therapy, exposure of prior therapies, biomarkers, and varying competitive sets; and underlying assumptions for treatment allocation and rates of progression through various therapies. Key challenges addressed include: + + Precise calculations of Patients on Therapy Kantar Health s U.S. OMA deeply examines complex treatment and care dynamics through a multi-stakeholder lens delivering key insights that inform your commercial and market access strategies. Our OMA team routinely evaluates stakeholder dynamics in the cancer market, including exploring the impact of healthcare reform on oncology care. Additionally, we assess the changing structure of the cancer care delivery system, focusing on the treatment and business challenges and opportunities faced by oncologists, patients and payers as a result of the coverage policy and reimbursement trends that influence prescribing and impact affordability. Our OMA report features 10 modules, including: Treatment Architecture this module leverages robust primary market research surveys of physicians to gain a detailed understanding the current clinical management of cancer patients by tumor type, site, disease stage, treatment modalities, and drug therapy use. + + Irregular dosing patterns +Treatment + discontinuations + + Linking lines of therapy + + Cancer Care Dynamics +Treatment + Dynamics Trends + + Tumor-Specific Cancer Treatment Dynamics Future Trends and Insights this module delivers expert insights on impending changes in the competitive landscape in each tumor market, including new product introductions and label expansions of market products. CancerNFluence : Oncology KOL Mapping this key opinion leader (KOL) mapping module, driven by our proprietary CancerNFluence offering, delivers profiles of leading physicians in the United States and Europe who influence treatment decisions across multiple cancer types. + + Re-Treatment + + Spanning treatment durations longer than one year + + Government Health Policy Trends + + Patient Influence and Affordability + + Payer Mix Simulations + + Immunotherapy in Oncology + + Distribution Channel Dynamics 10 11

FOR MORE INFORMATION Please contact us at info@kantarhealth.com, or visit www.kantarhealth.com. ABOUT KANTAR HEALTH Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership. Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.